PT  - JOURNAL ARTICLE
ED  - ,
TI  - Potassium para-aminobenzoate (potaba) in scleroderma
AID  - 10.1136/dtb.6.12.47
DP  - 1968 Jun 07
TA  - Drug and Therapeutics Bulletin
PG  - 47--48
VI  - 6
IP  - 12
4099  - http://dtb.bmj.com/content/6/12/47.short
4100  - http://dtb.bmj.com/content/6/12/47.full
SO  - Drug Ther Bull1968 Jun 07; 6
AB  - In the past fifteen years there have been numerous reports on the treatment of scleroderma and related conditions with potassium para-aminobenzoate (Potaba - Glenwood Laboratories). The use of this ‘antifibrotic’ treatment is empirical. p-Aminobenzoic acid (PABA) is not known to affect fibrosis or fibrous tissue experimentally. Many bacteria require it for the synthesis of folic acid, and sulphonamides antagonise their utilisation of it.